Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio (NASDAQ: PASG) has out-licensed three pediatric gene therapy programs to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson. The deal includes exclusive, worldwide rights for PBGM01 (GM1 gangliosidosis), PBKR03 (Krabbe disease), and PBML04 (metachromatic leukodystrophy). Passage Bio will receive initial payments of $10 million, with potential for up to $124 million in additional milestones and future royalties.
The company also entered a new strategic research collaboration with GEMMA Biotherapeutics, focusing on CNS indications including Huntington's disease. This transaction is expected to extend Passage Bio's operating cash runway to the end of Q2 2026, allowing the company to focus on advancing its lead asset, PBFT02, in multiple adult neurodegenerative diseases.
Passage Bio (NASDAQ: PASG) has received positive feedback from the FDA on expanding its upliFT-D trial of PBFT02 to include FTD-C9orf72 patients. The company plans to amend the ongoing Phase 1/2 global study protocol to introduce this new patient population, with dosing expected to begin in 1H 2025. This expansion is supported by compelling preclinical evidence and safety data from the first cohort of FTD-GRN patients treated with PBFT02.
FTD-C9orf72 affects approximately 21,000 individuals in the US and Europe. The FDA has granted PBFT02 Fast Track and Orphan Drug designations, while the European Commission has also given it Orphan designation. This development could bring new hope to an underserved patient community with clinical trial options.
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, will present at the Goldman Sachs 45th Annual Global Healthcare Conference. President and CEO William Chou, M.D., will deliver the presentation on June 12, 2024, at 4:00 p.m. ET. The live webcast and a 30-day replay will be accessible on Passage Bio's website.
Passage Bio (Nasdaq: PASG), a clinical stage genetic medicines company, announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship. This award honors Dr. Tachi Yamada, the co-founder and former Chairman, and supports life sciences students in Pennsylvania. Carrie, pursuing a degree in Biological Science with a minor in Neuroscience, has a passion for neurology and aims to provide healthcare to underserved communities. The scholarship provides financial assistance and a mentor from Passage Bio for professional growth.
Passage Bio (NASDAQ: PASG) reported its Q1 2024 financial results and provided business updates, including advances in its global upliFT-D clinical trial for FTD-GRN. The trial's Dose 1 PBFT02 consistently elevated CSF progranulin at six months in two patients. All five patients in Cohort 1 have been dosed, with safety and biomarker data expected in 2H 2024. Cohort 2 dosing is planned to start by the end of 1H 2024. The company initiated discussions with the FDA for using PBFT02 to treat FTD-C9orf72, with feedback expected in 2H 2024. Financially, the company ended Q1 with $104.5 million in cash, projecting a cash runway into Q4 2025. Net loss decreased to $16.7 million from $34.3 million year-over-year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Passage Bio (PASG)?
What is the market cap of Passage Bio (PASG)?
